Abstract:Direct radiolabeling of proteins can result in the loss of targeting activity, requires highly customized procedures, and yields heterogeneous products. Here we describe a novel imaging complex comprised of a standardized Tc-99m-radiolabeled adapter protein noncovalently bound to a "Docking tag" fused to a "Targeting protein". The assembly of this complex is based on interactions between human 109-amino acid (HuS) and 15-amino acid (Hu-tag) fragments of ribonuclease 1, which serve as an "Adapter protein" and a Docking tag, respectively. Methods: HuS modified with hydrazinonicotinamicle (HYNIC) was radiolabeled using Tc-99m-tricine to a specific activity of 3.4-7.4 MBq/I.Lg. Protein complexes were then formed by mixing Tc-99m-HuS with equimolar amounts of either Hu-tagged VEGF(121) (Hu-VEGF [vascular endothelial growth factor]) or Hu-tagged anti-VEGFR-2 single-chain antibody (Hu-P4G7) and incubating on ice for 15 min. 4T1 luc/gfp luciferase-expressing murine mammary adenocarcinoma cells (1 X 10(4)) were implanted subcutaneously or injected intravenously into BALB/c mice. Bioluminescent imaging (BLI) was performed 10 d later. Immediately after BLI visualization of tumor, 18.5-37 MBq of tracer (5-10 mug of protein) were injected via tail vein. One hour later planar or SPECT images were obtained, followed by killing the mice. Results: There was significantly (P = 0.0128) increased uptake of Tc-99m-HuS/Hu-VEGF (n = 10) within subcutaneous tumor as compared with Tc-99m-HuS/Hu-P4G7 (n = 5) at biodistribution assay (2.68 +/- 0.75 vs. 1.8 +/- 0.21; tumor-to-subcutaneous tissue [ratio of specific activities], respectively), despite similar molecular weights. The focal 99mTc-HuS/Hu-VEGF uptake seen on planar images (3.44 +/- 1.16 [tumor to soft-tissue background]) corresponded directly to the locations of tumor observed by BLI. Region of interest analyses of SPECT images revealed a significant increase of 99mTc-HuS/Hu-VEGF (n = 5) within the lungs with BLI-detectable pulmonary tumor nodules as compared with controls (n 4) (right: 4.47 +/- 2.07 vs. 1.79 +/- 0.56; left: 3.66 +/- 1.65 vs. 1.62 +/- 0.45, tumor lung [counts/pixel]/normal lung [counts/pixel], respectively). Conclusion: (99m)TcHuS/Hu-VEGF complex is stable for at least 1 In in vivo and can be effectively used to image mouse tumor neovasculature in lesions as small as several millimeters in soft tissue. We expect that a similar approach can be adapted for in vivo delivery of other targeting proteins of interest without affecting their bioactivity.

Synthesis and single photon emission computed tomography imaging evaluation with 99mTc-labeled bevacizumab in colorectal cancer xenografts

Molecular Imaging of Melanoma VEGF-expressing Tumors through [ 99m Tc]Tc-HYNIC-Fab(Bevacizumab)

Design and Preliminary Assessment of 99m Tc-labeled Ultrasmall Superparamagnetic Iron Oxide-Conjugated Bevacizumab for Single Photon Emission Computed Tomography/magnetic Resonance Imaging of Hepatocellular Carcinoma

Positron Emission Tomography And Near-Infrared Fluorescence Imaging Of Vascular Endothelial Growth Factor With Dual-Labeled Bevacizumab

Preparation and bioevaluation of 111 In-DTPA-avastin for non-invasive tumor targeted imaging

Integrin Αvβ3-Targeted SPECT/CT for the Assessment of Bevacizumab Therapy in Orthotopic Lung Cancer Xenografts.

Design and Initial Evaluation of USPIO Modified Bevacizumab As a Hybrid SPECT/MRI Probe to Hepatoma Carcinoma Cells

Synthesis, Radiolabeling, and Biodistribution Study of a Novel DOTA-Peptide for Targeting Vascular Endothelial Growth Factor Receptors in the Molecular Imaging of Breast Cancer

A Novel Tc-99m-Labeled Molecular Probe For Tumor Angiogenesis Imaging In Hepatoma Xenografts Model: A Pilot Study

Initial evaluation of 99m Tc‐labeled anti‐CEA scFv for micro‐SPECT imaging in mice with colorectal cancer

Initial Evaluation of 99m Tc-labeled Anti-Carcinoembryonic Antigen Single-Chain Fragment Variable for Micro-Single-photon Emission Computed Tomography Imaging in Mice with Colorectal Cancer.

Tumor Imaging Using a Standardized Radiolabeled Adapter Protein Docked to Vascular Endothelial Growth Factor.

Radiolabeling and Evaluation of (64)Cu-Dota-f56 Peptide Targeting Vascular Endothelial Growth Factor Receptor 1 in the Molecular Imaging of Gastric Cancer.

Biometabolic Distribution of 99Mtc-3Prgd2 and Its Potential Value in Monitoring Chemotherapeutic Effects

Bevacizumab and near infrared probe conjugated iron oxide nanoparticles for vascular endothelial growth factor targeted MR and optical imaging.

Primary Preclinical and Clinical Evaluation of 68Ga-Dota-tmvp1 As a Novel VEGFR-3 PET Imaging Radiotracer in Gynecological Cancer

Biodistribution and Pharmacokinetics of 99tcm Labeled Carbohydrated Peptides in Mice Bearing Tumors

18F-Labeled Magnetic Nanoparticles for Monitoring Anti-Angiogenic Therapeutic Effects in Breast Cancer Xenografts.

Positron Emission Tomography Imaging of Vascular Endothelial Growth Factor Receptor Expression with 61Cu-Labeled Lysine-Tagged VEGF121

[99mTc]-labeling and evaluation of a new linear peptide for imaging of glioblastoma as a αvβ3-positive tumor

Studies on the distribution and radioimmunoimaging of 99m Tc-labeled 5-fluorouracil loaded immunological nanoparticles in tissues and human gastric carcinoma xenografts